BRUSSELS (dpa-AFX) - UCB (UCB.BR) announced the FDA has approved the first self-administered once-daily autoinjector administration option for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive with ZILBRYSQ. The ZILBRYSQ autoinjector is designed to automatically deliver a pre-defined dose when activated against the skin.
Prior to the autoinjector's approval, ZILBRYSQ was available as a self-administered prefilled syringe. UCB expects the autoinjector to be available commercially in first quarter, 2027.
UCB shares are trading at 203.30 euros on Euronext Brussels, down 1.31%.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
